 KalVista Pharmaceuticals, Inc. NASDAQ:KALV, a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced potential impact of coronavirus disease 2019 COVID-19 on its ongoing operations and provided revised financial guidance that activities are funded into at least early 2022. 